Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ucb S.A. (UCBJF)

Ucb S.A. (UCBJF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 34,779,680
  • Shares Outstanding, K 189,020
  • Annual Sales, $ 5,684 M
  • Annual Income, $ 371,230 K
  • EBIT $ 0 M
  • EBITDA $ 1,332 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow 23.28
  • Price/Book 3.64
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
269.3000 +6.92%
on 12/29/25
302.1100 -4.69%
on 12/05/25
+4.0025 (+1.41%)
since 12/02/25
3-Month
242.6600 +18.66%
on 11/04/25
306.7900 -6.14%
on 10/14/25
-2.0600 (-0.71%)
since 10/02/25
52-Week
150.7000 +91.07%
on 04/10/25
306.7900 -6.14%
on 10/14/25
+87.9400 (+43.97%)
since 01/02/25

Most Recent Stories

More News
UCB SA (0NZT) Gets a Buy from Berenberg Bank

In a report released yesterday, from Berenberg Bank maintained a Buy rating on UCB SA, with a price target of €290.00. The company’s shares closed yesterday at €258.30.Elevate Your Investing Strategy:...

UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
Barclays Keeps Their Buy Rating on UCB SA (0NZT)

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA, with a price target of €270.00. The company’s shares closed last Friday at €257.24.Elevate Your Investing...

UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
TD Cowen Sticks to Its Buy Rating for UCB SA (0NZT)

TD Cowen analyst Stacy Ku maintained a Buy rating on UCB SA today and set a price target of €300.00. The company’s shares closed yesterday at €257.96.Elevate Your Investing Strategy: Take advantage...

UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
Deutsche Bank Sticks to Their Buy Rating for UCB SA (0NZT)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on UCB SA today and set a price target of €285.00. The company’s shares closed last Friday at €250.10.Elevate Your Investing Strategy:...

UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
Goldman Sachs Remains a Buy on UCB SA (0NZT)

Goldman Sachs analyst Rajan Sharma reiterated a Buy rating on UCB SA on September 29 and set a price target of €255.00. The company’s shares closed yesterday at €244.62.Elevate Your Investing Strategy:...

UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

BRUSSELS , Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy...

UCB : 31.41 (+0.61%)
UCBJF : 287.9400 (-1.92%)
UCBJY : 137.4800 (-1.63%)
Why Zogenix Flew Higher Before Leveling Off This Week

The company attracts a determined suitor from abroad.

UCBJF : 287.9400 (-1.92%)
ZGNX : 26.68 (+1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson's disease. It also provides therapy in the areas of oncology, immunology, inflammation,...

See More

Key Turning Points

3rd Resistance Point 312.8799
2nd Resistance Point 303.2300
1st Resistance Point 298.4050
Last Price 287.9400
1st Support Level 283.9300
2nd Support Level 274.2800
3rd Support Level 269.4550

See More

52-Week High 306.7900
Last Price 287.9400
Fibonacci 61.8% 247.1636
Fibonacci 50% 228.7450
Fibonacci 38.2% 210.3264
52-Week Low 150.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar